Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smart sugar sensors may improve recovery from complex pancreatic surgery

NCT ID NCT06755788

Disease control Sponsor: Peking Union Medical College Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This study tests whether using a real-time continuous glucose monitor (RT-CGM) during pancreaticoduodenectomy (a complex surgery) helps keep patients' blood sugar in a safe range and improves recovery. About 246 adults scheduled for this surgery will be randomly assigned to standard care or RT-CGM-guided care. The main goal is to see how much time blood sugar stays in the target range during the operation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
real-time continuous glucose monitor (RT-CGM)
What this could lead to
If it works, this approach could help surgeons maintain safer blood sugar levels during major pancreatic surgery, potentially reducing complications and speeding recovery.
What could go wrong
This is a single-center trial with 246 participants, so results may not apply to all hospitals or surgeries. The device itself carries a low risk of skin irritation or sensor inaccuracy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

246 people

The number who actually took part.

Started

Jan 2025

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 * Scheduled for pancreaticoduodenectomy * ASA classification I-III Exclusion Criteria: * Emergency surgery * scheduled for MRI the day before surgery * Allergy to CGM sensor * Communication barriers or refusal to participate * BMI \< 18.5 kg/m²

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Continuous glucose monitoring are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

distal biliary tract carcinoma exocrine pancreatic carcinoma periampullary adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Continuous glucose monitoring

Contacts and locations

Locations

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.